|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.52 USD | -1.27% |
|
-9.64% | +6.16% |
| 07-21 | Dexcom Insider Sold Shares Worth $2,041,999, According to a Recent SEC Filing | MT |
| 07-16 | Truist Adjusts Price Target on DexCom to $87 From $80, Maintains Buy Rating | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.85 | 4.74 | 6.41 | 5.88 | 8.89 | |||||
Return on Total Capital | 4.52 | 5.77 | 8.35 | 8.01 | 12.9 | |||||
Return On Equity % | 7.59 | 16.35 | 25.78 | 27.63 | 34.5 | |||||
Return on Common Equity | 7.59 | 16.35 | 25.78 | 27.63 | 34.5 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 68.63 | 64.72 | 63.19 | 60.46 | 60.1 | |||||
SG&A Margin | 32.44 | 34.37 | 32.72 | 31.88 | 27.69 | |||||
EBITDA Margin % | 14.95 | 18.24 | 21.64 | 20.28 | 24.96 | |||||
EBITA Margin % | 11.52 | 13.7 | 17.57 | 15.78 | 20.26 | |||||
EBIT Margin % | 11.52 | 13.44 | 16.5 | 14.88 | 19.56 | |||||
Income From Continuing Operations Margin % | 6.32 | 11.73 | 14.95 | 14.29 | 17.94 | |||||
Net Income Margin % | 6.32 | 11.73 | 14.95 | 14.29 | 17.94 | |||||
Net Avail. For Common Margin % | 6.32 | 11.73 | 14.95 | 14.29 | 17.94 | |||||
Normalized Net Income Margin | 4.89 | 8.39 | 12.22 | 10.99 | 14.59 | |||||
Levered Free Cash Flow Margin | -8.04 | 8 | 13.04 | 13.7 | 15.43 | |||||
Unlevered Free Cash Flow Margin | -5.48 | 8.4 | 13.39 | 14 | 15.68 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.53 | 0.56 | 0.62 | 0.63 | 0.73 | |||||
Fixed Assets Turnover | 3.27 | 2.87 | 3.12 | 3.12 | 3.07 | |||||
Receivables Turnover (Average Receivables) | 5.19 | 4.74 | 4.29 | 4.07 | 4.2 | |||||
Inventory Turnover (Average Inventory) | 2.59 | 2.76 | 2.76 | 2.79 | 3.18 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 5.11 | 1.99 | 2.84 | 1.47 | 1.88 | |||||
Quick Ratio | 4.5 | 1.74 | 2.39 | 1.23 | 1.53 | |||||
Operating Cash Flow to Current Liabilities | 0.61 | 0.36 | 0.48 | 0.34 | 0.67 | |||||
Days Sales Outstanding (Average Receivables) | 70.27 | 76.99 | 85 | 89.83 | 86.98 | |||||
Days Outstanding Inventory (Average Inventory) | 140.68 | 132.23 | 132.16 | 131.37 | 114.96 | |||||
Average Days Payable Outstanding | 73.63 | 75.58 | 60.55 | 73.05 | 64.65 | |||||
Cash Conversion Cycle (Average Days) | 137.32 | 133.65 | 156.61 | 148.15 | 137.28 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 83.59 | 100.82 | 125.63 | 123.36 | 50.85 | |||||
Total Debt / Total Capital | 45.53 | 50.2 | 55.68 | 55.23 | 33.71 | |||||
LT Debt/Equity | 82.54 | 63.42 | 124.38 | 64.71 | 49.82 | |||||
Long-Term Debt / Total Capital | 44.96 | 31.58 | 55.13 | 28.97 | 33.03 | |||||
Total Liabilities / Total Assets | 53.71 | 60.46 | 66.98 | 67.57 | 56.69 | |||||
EBIT / Interest Expense | 2.81 | 21.03 | 29.44 | 31.58 | 49.83 | |||||
EBITDA / Interest Expense | 3.97 | 30.37 | 40.26 | 44.89 | 65.5 | |||||
(EBITDA - Capex) / Interest Expense | 0.08 | 10.75 | 28.61 | 26.01 | 45.63 | |||||
Total Debt / EBITDA | 4.73 | 3.81 | 3.18 | 3.04 | 1.17 | |||||
Net Debt / EBITDA | -2.14 | -0.54 | -0.15 | 0.02 | -0.5 | |||||
Total Debt / (EBITDA - Capex) | 221.42 | 10.75 | 4.48 | 5.25 | 1.67 | |||||
Net Debt / (EBITDA - Capex) | -99.89 | -1.54 | -0.22 | 0.03 | -0.72 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 27.08 | 18.84 | 24.49 | 11.34 | 15.6 | |||||
Gross Profit, 1 Yr. Growth % | 31.28 | 12.06 | 21.55 | 6.52 | 14.92 | |||||
EBITDA, 1 Yr. Growth % | 3.36 | 51.72 | 43.25 | 4.34 | 42.3 | |||||
EBITA, 1 Yr. Growth % | -5.81 | 47.94 | 57.89 | 0.03 | 48.41 | |||||
EBIT, 1 Yr. Growth % | -5.81 | 47.18 | 52.79 | 0.38 | 51.97 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -68.66 | 57.31 | 58.7 | 6.41 | 45.14 | |||||
Net Income, 1 Yr. Growth % | -68.66 | 57.31 | 58.7 | 6.41 | 45.14 | |||||
Normalized Net Income, 1 Yr. Growth % | -16.98 | 52.12 | 81.39 | -0.2 | 53.51 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -69.37 | 54.74 | 58.06 | 9.35 | 46.73 | |||||
Accounts Receivable, 1 Yr. Growth % | 20.02 | 38.69 | 36.53 | 3.27 | 20.92 | |||||
Inventory, 1 Yr. Growth % | 52.24 | 1.38 | 57.84 | -6.31 | 15.94 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 46.22 | 27.61 | 4.31 | 18.42 | 16.72 | |||||
Total Assets, 1 Yr. Growth % | 13.36 | 9.29 | 16.19 | 3.51 | -2.23 | |||||
Tangible Book Value, 1 Yr. Growth % | 23.33 | -2.59 | -1.24 | 3.54 | 34.13 | |||||
Common Equity, 1 Yr. Growth % | 23.27 | 4.39 | -2.96 | 1.64 | 30.6 | |||||
Cash From Operations, 1 Yr. Growth % | -6.96 | 51.3 | 11.8 | 32.2 | 45.6 | |||||
Capital Expenditures, 1 Yr. Growth % | 95.58 | -6.27 | -35.14 | 51.65 | 1.31 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -314.58 | -252.31 | 86.43 | 15.86 | 28.69 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -192.74 | -273.24 | 83.04 | 15.28 | 28.02 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 28.8 | 22.89 | 21.63 | 17.73 | 13.45 | |||||
Gross Profit, 2 Yr. CAGR % | 34.32 | 21.29 | 16.71 | 13.79 | 10.64 | |||||
EBITDA, 2 Yr. CAGR % | 41.87 | 22.41 | 45.97 | 22.25 | 21.85 | |||||
EBITA, 2 Yr. CAGR % | 40.8 | 14.9 | 53.12 | 25.67 | 21.84 | |||||
EBIT, 2 Yr. CAGR % | 40.8 | 14.29 | 49.96 | 23.84 | 23.51 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 23.7 | -21.22 | 58 | 29.95 | 24.27 | |||||
Net Income, 2 Yr. CAGR % | 23.7 | -21.22 | 58 | 29.95 | 24.27 | |||||
Normalized Net Income, 2 Yr. CAGR % | 35.64 | 14.54 | 69.95 | 34.69 | 23.78 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 18.71 | -21.41 | 56.39 | 31.47 | 26.67 | |||||
Accounts Receivable, 2 Yr. CAGR % | 34.03 | 29.02 | 37.61 | 18.74 | 11.74 | |||||
Inventory, 2 Yr. CAGR % | 72.7 | 26.32 | 26.5 | 21.6 | 3.16 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 50.52 | 36.6 | 15.37 | 11.14 | 17.57 | |||||
Total Assets, 2 Yr. CAGR % | 42.5 | 12.1 | 12.69 | 9.67 | 0.6 | |||||
Tangible Book Value, 2 Yr. CAGR % | 59.66 | 4.03 | -1.91 | 1.12 | 17.85 | |||||
Common Equity, 2 Yr. CAGR % | 59.72 | 8.03 | 0.65 | -0.69 | 15.22 | |||||
Cash From Operations, 2 Yr. CAGR % | 18.62 | 18.65 | 30.06 | 21.57 | 38.74 | |||||
Capital Expenditures, 2 Yr. CAGR % | 47.04 | 35.39 | -22.03 | -0.83 | 23.95 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 182.61 | 31.98 | 87.18 | 47.7 | 22.81 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 46.72 | 29.97 | 98.52 | 45.96 | 22.17 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 33.39 | 25.39 | 23.42 | 18.1 | 17.01 | |||||
Gross Profit, 3 Yr. CAGR % | 36.28 | 26.44 | 21.37 | 13.21 | 14.16 | |||||
EBITDA, 3 Yr. CAGR % | 32.55 | 42.89 | 30.31 | 30.52 | 28.6 | |||||
EBITA, 3 Yr. CAGR % | 14.83 | 40.98 | 28.2 | 32.86 | 32.84 | |||||
EBIT, 3 Yr. CAGR % | 14.83 | 40.09 | 25.9 | 31.18 | 32.59 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 6.77 | 50 | -0.5 | 38.5 | 34.83 | |||||
Net Income, 3 Yr. CAGR % | 6.77 | 50 | -0.5 | 38.5 | 34.83 | |||||
Normalized Net Income, 3 Yr. CAGR % | 3.96 | 55.37 | 33.48 | 42.45 | 40.69 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 2.46 | 44.16 | -0.8 | 38.81 | 36.37 | |||||
Accounts Receivable, 3 Yr. CAGR % | 31.4 | 35.57 | 31.48 | 25.05 | 19.46 | |||||
Inventory, 3 Yr. CAGR % | 71.61 | 46.22 | 36.06 | 14.45 | 18.87 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 69.39 | 42.46 | 24.85 | 16.38 | 12.97 | |||||
Total Assets, 3 Yr. CAGR % | 36.41 | 31.06 | 13.45 | 9.54 | 5.55 | |||||
Tangible Book Value, 3 Yr. CAGR % | 50.62 | 30.78 | 2.25 | -0.13 | 11.11 | |||||
Common Equity, 3 Yr. CAGR % | 50.29 | 34.17 | 4.24 | 0.98 | 8.81 | |||||
Cash From Operations, 3 Yr. CAGR % | 53.14 | 28.64 | 16.32 | 30.77 | 29.1 | |||||
Capital Expenditures, 3 Yr. CAGR % | 79.67 | 26.55 | 5.94 | -2.67 | -0.12 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 19.05 | 111.37 | 52.34 | 60.05 | 41.61 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 0.84 | 57.68 | 49.67 | 66.16 | 40.24 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 33.69 | 32.28 | 28.56 | 22.27 | 19.33 | |||||
Gross Profit, 5 Yr. CAGR % | 34.74 | 30.79 | 28.09 | 21.22 | 16.96 | |||||
EBITDA, 5 Yr. CAGR % | 49.57 | 82.24 | 37.89 | 35.07 | 26.86 | |||||
EBITA, 5 Yr. CAGR % | 34.58 | 56.48 | 27.85 | 34.93 | 25.62 | |||||
EBIT, 5 Yr. CAGR % | 34.58 | 55.88 | 26.26 | 33.35 | 24.94 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 18.72 | 46.71 | 33.63 | 41.63 | 8.75 | |||||
Net Income, 5 Yr. CAGR % | 18.72 | 46.71 | 33.63 | 41.63 | 8.75 | |||||
Normalized Net Income, 5 Yr. CAGR % | 24.19 | 51.73 | 32.94 | 46.74 | 29.58 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 14.58 | 41.46 | 29.3 | 38.94 | 9.39 | |||||
Accounts Receivable, 5 Yr. CAGR % | 38.29 | 39.65 | 33.85 | 28.57 | 23.2 | |||||
Inventory, 5 Yr. CAGR % | 51.08 | 52.64 | 52.91 | 35.82 | 21.8 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 52.08 | 50.8 | 45.27 | 28.99 | 21.89 | |||||
Total Assets, 5 Yr. CAGR % | 64.58 | 42.92 | 26.74 | 22.04 | 8.12 | |||||
Tangible Book Value, 5 Yr. CAGR % | 51.88 | 36.54 | 24.25 | 18 | 8.22 | |||||
Common Equity, 5 Yr. CAGR % | 51.32 | 38.43 | 25.54 | 18.96 | 8.5 | |||||
Cash From Operations, 5 Yr. CAGR % | 51.09 | 48.73 | 43.46 | 25.76 | 24.81 | |||||
Capital Expenditures, 5 Yr. CAGR % | 47.52 | 40.77 | 28.66 | 14.79 | 12.81 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 48.43 | 66.05 | 32.27 | 86.27 | 40.03 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 37.04 | 56.02 | 29.96 | 55.38 | 38.26 |
- Stock Market
- Stocks
- DXCM Stock
- Financials DexCom, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















